- Home
- KPRX vs KNRX Comparison
KPRX vs KNRX Comparison
Compare KPRX & KNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | KNRX |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.9M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KPRX | KNRX |
|---|---|---|
| Price | $2.67 | $0.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 4.8M |
| Earning Date | 05-08-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.76 | $0.30 |
| 52 Week High | $2.95 | $3.45 |
Technical Indicators
Market Signals| Indicator | KPRX | KNRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 40.06 |
| Support Level | $2.45 | $0.33 |
| Resistance Level | $2.72 | $0.49 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 84.78 | 12.79 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.